Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World data sought on breast cancer drug in russia

NCT ID NCT07281001

First seen Jan 06, 2026 · Last updated May 25, 2026 · Updated 27 times

Summary

This study will collect and analyze real-world medical records from 60 Russian adults with advanced HER2-positive breast cancer who have already received at least one cycle of trastuzumab deruxtecan. The goal is to see how well the drug works in everyday practice, including how long it keeps cancer from growing and what side effects occur. No new treatments are given; it is an observational review of existing data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation

    RECRUITING

    Moscow, 115522, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.